Trial Profile
A Phase 3, Double-Blind, Multicenter, Randomized, Placebo-Controlled Trial Evaluating Repeated Courses of Aztreonam for Inhalation Solution/Aztreonam 75 mg Powder and Solvent for Nebuliser Solution in Subjects with non-CF Bronchiectasis and Gram-Negative Endobronchial Infection
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 08 Oct 2021
Price :
$35
*
At a glance
- Drugs Aztreonam (Primary)
- Indications Bronchiectasis; Gram-negative infections
- Focus Registrational; Therapeutic Use
- Acronyms AIR-BX2
- Sponsors Gilead Sciences
- 07 Apr 2020 Results of post hoc analysis of AIR-BX1 and AIR-BX2 studies published in the European Respiratory Journal
- 12 May 2019 Results of a post-hoc analysis of AIR-BX1 and AIR-BX2 trials assessing the airway bacterial load and inhaled antibiotic response in Bronchiectasis, published in the American Journal of Respiratory and Critical Care Medicine
- 11 Sep 2013 Results presented at the 23rd Annual Congress of the European Respiratory Society.